Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index
Sign Up to like & getrecommendations! Published in 2019 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2019.1686057
Abstract: Abstract Background: The Lémann Index (LI) was recently developed to evaluate the cumulative bowel damage in patients with Crohn’s disease (CD). Aims: To search for a difference between adalimumab and azathioprine to halt the progression… read more here.
Keywords: bowel; bowel damage; progression bowel; azathioprine ... See more keywords